A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 24, 2025

Primary Completion Date

June 8, 2026

Study Completion Date

July 6, 2026

Conditions

Cancer Cachexia

Interventions

DRUG

GFS202A injection

Participants will receive GFS202A intravenously every 3 weeks (Q3W) in a 21-day cycle. The treatment duration was 12 weeks.

Trial Locations (1)

RECRUITING

Sun-Yat Sen university cancer center, Guangzhou

All Listed Sponsors

lead

Genfleet Therapeutics (Shanghai) Inc.

INDUSTRY

NCT06898255 - A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia | Biotech Hunter | Biotech Hunter